Meeting Minutes of the Chelsea Board of Health March 8, 2022

Attendance: Names of members and Participants

Board members, City of Chelsea staff and guests were introduced.

Board Members:

- Ola Bayode
- Corinna Culler
- Allen Jackson
- Josh Merson
- Dr. Dean Xerras

City of Chelsea Staff:

- Dr. Flor Amaya, Director of Public Health
- Paula McHatton, Public Health Nurse
- Oriana Reilly, Dept. of Housing and Community Development
- Stephon Treadway, Asst. City Solicitor

Guests/Members of the Public:

- Irene Bosch, The Chelsea Project
- Dario Camacho, La Collaborativa
- Dinanyili Paulino, La Collaborativa
- Dan Cortez, Chelsea Police Department
- Barry Keppard, Metropolitan Area Planning Council
- · Ann Kissel, North Suffolk Public Health Collaborative

Adoption of the Minutes of the February Meetings

The minutes of the February meeting were adopted unanimously by members present at the meeting.

The Chelsea Project Rapid Test Study Update

Irene Bosch and Dr. Amaya spoke about a rapid test study conducted by the Chelsea Project, in collaboration with the Chelsea Housing Authority where residents received rapid tests and instructions on their proper use. The program initially focused on housing authority residents with mobility limitations who were not able to easily access the city's **Stop the Spread** testing sites but has since been expanded to include city employees.

Highlights of Irene Bosch's presentation included:

So far, 1,103 tests have been collected and analyzed through this study.
 Participants upload photos of their test results to an online portal. Participants that test positive receive follow-up and continue to test until they test negative again or complete guarantine.

- Using data gathered through the project, Bosch was able to show how the Omicron variant peak moved through the testing population in housing authority residents.
- The study uses a complex protocol to validate test results, and the study protocol calls for participants to test at home while quarantining, enabling the study to monitor positivity over time.
- The program was one of two organizations awarded \$1.8m by the Regan-Udall Foundation for the FDA to study the real-world performance of COVID-19 tests.

In discussing the program's expansion plans, Bosch noted plans to increase the number of sites where the program is offered and to find better ways to share the data with users, and other public health authorities. Dr. Amaya added that they would like to increase usership for Chelsea residents interested in the program and make testing more widely available in the community.

COVID-19 Community Level Metric Update

Ann Kissel discussed the COVID-19 incidence rates, vaccination updates and observations on preparing for the future of COVID-19 and its impacts. Of note:

- COVID-19 case incidence continues to decline in Chelsea there were fourteen cases between 2/27/22 3/5/2022, or 34.3 cases/100.000 individuals.
- From 2/1/22 3/1/22, the city saw an increase in individuals receiving booster shots among all age groups.
- The former framework from the CDC for preventing COVID-19 infection focused on transmission level, categorizing communities as at low, moderate, or substantial risk for COVID-19 transmission. The CDC's revised framework includes additional metrics, including severity and healthcare system burden. The goal of the new framework is to prevent significant illness, minimize the burden on healthcare facilities and protecting the most vulnerable. Under this new framework, Massachusetts is in the green or low risk category. Kissel also discussed reservations some in the public health field have expressed about the change this new model represents, including that it may be difficult to get people to go back to masking when levels do go up, and the focus on "testing to treat" may be creating a barrier for people who are un- or underinsured.
- Kissel shared a spreadsheet she began showing suggestions for actions that could be taken at each level to address transmission risk in Chelsea, using the CDC's new framework as a guide,

Dr. Xerras questioned whether the word "mitigation" should be used in place of "prevention" in the new model since the strategies and action plans the CDC outlined seemed to be focused on the mitigation of COVID-19's impact. Kissel noted that was the CDC's language.

Ola Bayode questioned how the city could raise more awareness of the impact of the underlying causes of COVID-19 infection. Kissel responded that she is planning to use new CDC data that focuses on chronic conditions to see who in Chelsea is impacted by those conditions and focusing on ways to integrate more people into the healthcare

system. Kissel added that they are working with the North Suffolk Collaborative on an educational campaign to help people become more knowledgeable around COVID infection/prevention strategies.

Irene Bosch wondered how the duration of immunity factored into these strategies, whether the mitigation strategies would be impacted by immunity level and the potential need for additional boosters. Kissel responded that they have thought about how an additional booster could be administered in late spring/early fall but noted that a second booster has not yet be recommended by the CDC. Dr. Xerras noted a New England Journal of Medicine study that showed that individuals who had contracted COVID-19 who had gotten vaccinated and boosted had immunity that lasted about 1 year. Dr. Amaya noted that booster rates are increasing among children and adults over 65.

Rodent Control Public Hearing

Dario Camacho and Dinanyili Paulino of La Collaborativa reported hearing concerns about rodents from the community and wanted time to be able to review the regulations with their members before they went into effect. Stephan Treadway commented that not all the impacted city agencies responsible for enforcement felt they had sufficient time to comment on the draft regulations and recommended continuing the public hearing until next month to allow for additional input from other City departments and the public.

Oriana Reilly noted that residents brought their rodent control issues to the City, and then she began developing recommendations to deal with a growing rodent population. The city met with the contractor responsible for rodent baiting and suggested looking at similar ordinances in Lynn.

Dr. Xerras commented that the regulations put the onus on permit holders to develop a plan for rodent control and mitigation. Paulino reported that residents feel there is not enough accountability for landlords/building owners for when there is a rodent control issue, or when the problem is not adequately addressed.

Corinna Culler asked Paulino whether there were specific types of buildings that were reporting rodent issues. She replied that there are various types of buildings where members reported rodent control issues, ranging from singe apartments to large developments. Camacho reported that they had created a map of locations where their members were having issues with rodents.

Dr. Amaya noted that the issues and concerns expressed by Paulino and her members do not seem to be adequately addressed in the draft regulations. Paulino agreed, adding that residents have rodent issues that the regulations should address.

Dan Cortez asked if La Collaborativa could overlay their "hot spot" map with current construction projects. He agreed to work on that and wondered if there could be a way for residents to request rodent mitigation from the city directly, given the number of absentee landlords in the city.

The public hearing will continue next month. People with questions should send their questions to Dr. Amaya.

Public Health Updates

Dr. Flor Amaya:

- Friday operations at the Senior Center will end as of March 18.
- **Stop the Spread** sites in Chelsea will be closed as of March 31. The city will be receiving rapid tests for those looking for testing.
- BIDMC is exploring options to maintain their current testing site.

Paula McHatton:

Communicable Diseases

- There was one case of norovirus reported in a person who had symptoms for one day. The person did not travel recently and hot not eaten any suspicious food.
- There was one case of salmonella reported in a person who experienced symptoms for three days, and then went to the hospital for dehydration. This person had not eaten any suspicious foods.
- There was one case of campylobacter infection in a person who experienced one day of symptoms. The person did not report any unusual food intake. They were given IV fluids and sent home.
- There were no reported TB cases, and three cases of the flu-A strain in the month of February.

COVID-19 Update

- To date, Chelsea has had 15,157 cases of COVID-19 since the beginning of the pandemic, no new cases were reported last week.
- The positivity rate has decreased from 3.18% at the last Board meeting to 1.49% last week.
- The incidence rate has also decreased from 22.4/100,00 at our last meeting to 7.9/100.00 last week.
- Chelsea Public Schools will continue their mask mandate requirement.

Action Items

 Continue to review rodent regulations and send questions to Dr. Amaya or Stephan Treadway.

Next Meeting: April 12, 2020.


The meeting adjourned at 7:05pm

| allenachsur | |
|----------------------|-----------|
| Welleyachsu | 4/12/2022 |
| Allen Jackson, Clerk | Date |


| New COVID-19 Cases Per 100,000 people in the past 7 days | Indicators | in the second | Medium | High |
|--|---|--|---|--|
| 4 | New COVID-19 admissions per 100,000 population (7-day total) | Company of the Compan | 10.0-19.9 | P000 |
| Fewer than 200 | Percent of staffed inpatient beds occupied by COVID-19 patients (7-day average) | | 10,0-14.9% | ¥15.0% |
| 200 or more | New COVID-19 admissions per 100,000 population (7-day lotal) | | <10,0 | ×100 |
| | Percent of staffed inpatient beds occupied by COVID-19 patients (7-day average) | | <10.0% | c10.0% |
| | | Preventative Behavior Recomm | | |
| | Vaccinations | Tanga persebagai da Jacob persebagai Persebagai da Persebagai da Persebagai da Persebagai da Persebagai da Persebagai da Persebagai da Persebagai Persebagai da Persebagai d | Stay up to date with COVID-19 vaccines and boosters Get tested if you have symptoms Get tested if you have symptoms | Striptip to data with COVID-19 vectories and broadure Southern Get backer's you have symptoms. |
| | Testing | | If you have household or social contact with someone at high risk for severe disease consider self- testing to detect infection before contact | Type here household in score considered; companies in flightest, for several disease, consider saft testing to detect intestion before company. |
| | Masking | Property of the second | People may choose to mask at any time. People with symptoms, a positive test, or apposure to someone-with COVID-19 should weer a mask - if you have household or social contact with someone at high risk for never disease consider washing a mask when indoors with them | TW is a spek fitting mask indone in public pagarges of resonation status (institution in 4.2 withoute and others indone community settings). |
| Individual- and household-level | Indoor Ventistion | | Maintain improved vanilation throughout indoor spaces when possible Follow CDC recommendations for isolation and | Maintain injuried variable remugnout papers spaces when possible Policy CPC recommendations by endator and |
| | Isolation/Quarantine | | quarentine, including getting tested if you are exposed to COVID-19 or have symptoms of COVID-19 | eremine, including (#this betadt now as expose to CCVID-10 or here symptoms of CCVID-10 |
| | Immunocompromised or high risk for severe disease individuals*** | Security Control of Securi | Have a plan for repid lesting if needed (e.g., having home lests or access to testing) "Talk to your healthcare provider about whether you are a candidate for treatments like oral antivirals, PFEP, and monoclonal antibodies Talk to your healthcare provider about whether you need to wear a mask and take other precautions (e.g., lessing) | A tieve a pfact for paid testing it marked (e.g., having home sever access to harring). This to you in methicine provider about which is you we a similar before a provider about which is you we a similar before a provider about which is you hashvar a provider about which is you have a provider you with greater protection. Consider a vesting non-sever lost it was a substitute in the provider about provider and provider you with greater protection. |
| | Vaccinations | | Distribute and administer vaccines to achieve high community vaccination coverage and ensure health | - Distribute and extractive processor to consist page constrately vectoration coverage and events health |
| | Testing | Market Programme (Market Market) (Market Market Ma | equity Ensure access to testing, including through point-of- care and arthoms tests for all people Consider implementing screening testing or other testing strategies for people who are exposed to COVID-19 in workplaces, schools, or other community settings as appropriate | equity |
| | Indoor Ventilation | | • Maintain improved ventilation in public indoor spaces | A Mainteen suppressed yes dispositive public indoor applica- |
| Community-level (as recommended by state or local authorities) | Immunocompromised or high risk for severe disease individuals | | Communicate with organizations and places that serve people who are immunocompromised or at high disk for severe disease to ensure they know how to get repid testing. Protect people at high risk for severe liness or death by ensuring equitable access to vaccination, testing, treatment, support services, and information. | Communication of proportion of places that save people who are immissioned promises on a figure to the proportion of the property decade to setups they know that to get much setting. Profess people is figure as for service three content by enabling application scores to view profession, setting the about a property of the property o |
| | Health Equity Promotion | The control of the co | Ensure access and equity in vaccination, testing, treatment, community outreach, support services for disproportionately affected opportations. Implement enhanced prevention measures in high-risk congregate settings. | Place of become and excelly an executable, freeling transmitting community outlineds, althogothers because the dispropriation of the productions. Implement extracted prevention measures in high subscripting in each type of the community of the |
| | N | orth Suffolk's Action Plan Toward | s Prevention | |
| armonomore nerell'elle Mittelene de la Million de l'en medicale million de la complète de l'alle and de l'elle | Vaccinations | | Facilitate additional vaccine clinic during evening and/or weekend | TO SECURE A SECURE OF THE PARTY OF THE PARTY. |
| | Testing Masking | | | Establig manuscry mask mandak sayerin (upply masks to accoming trace spaces (i.e. growy server, christ) |
| Cheisea | Indoor Ventilation | | | |
| | immunocompromised or high risk for severe disease individuals | | | |
| pro-page-year agony page-year and page-year | Health Equity Promotion | | | |
| | Vaccinations Testing | | | |
| Revere | Masking Indoor Ventiation | | | |
| Revere | isolation/Quarantine immunocompromised or high risk for | | | |
| | severe disease individuals Health Equity Promotion | | | |
| The same of the sa | Vaccinations Testing | | | |
| Winthrop | Masking Indoor VenNation Isolation/Quarantine Immunocompromised or high risk for severe disease individuals Health Equity Promotion | | | |

[&]quot;At all levels, people can wear a mask based on personal preference, informed by personal level of risk. People with symptoms, a positive lest, or exposure to someone with COVID-19 should wear a mask.


"If you test positive for COVID-19 and have one or more beath conditions that increase your risk of becoming very sick, treatment may be available. Confact a health professional right away after a positive (est to determine if you may be eligible, even if your symptoms are mild right now. Don't delay. Treatment must be started within the first law days to be effective.




Chelsea Project _ Total participants (1103 tests)




Chelsea Project Housing Authority





Direct antigen rapid tests



Chelsea Project Protocol_FDA grant

500 for PCR confirmation

Confirmatory qRT-PCR

Repeat weekly or biweekly 1. Antigen lange lipload li



ABOUT - PROGRAMS - NEWS AND EVENTS -

COVID-19

(<u>a</u>)

News

🤻 I NEWS AND EVENTS 🦸 REAGAN-UDALL FOUNDATION FOR THE FDA AWARDS \$1.6 MILLION IN RESEARCH FUNDING FOR STUDIES ON THE REAL-WORLD PERFORMANCE OF COVID-19 TESTS



Reagan-Udall Foundation for the FDA Awards \$1.8 Million in Research Funding for Studies on the Real-World Performance of COVID-19 Tests

Beth Israel Deaconess Medical Center and IDx20 with The Chelsea Project Named as Awardees

(March 1, 2022) The Reagan-Udall Foundation for the FDA (FDA Foundation) awarded \$1.8 million in funding for two research projects evaluating the Real-World Performance of In Vitro Diagnostics (PIVD). Beth Israel Deaconess Medical Center will receive \$898,045 to study antigen and molecular COVID-19 tests using real-world patient data. IDx20 will receive \$893,500 to compare the performance of COVID-19 antigen tests in clinical settings versus real-world data collection. Their project includes a coalition of teams from the City of Chelsea, MA.



Specific Aims

- Validate antigen tests in the laboratory using both qualitative and quantitative methods to evaluate the performance of antigen tests.
- Measure clinical positive and negative percent agreement data compared to the gold standard detection method, qRT-PCR, for four or more antigen tests self-administered in at least two different real world use settings: senior living facilities and other Chelsea residents.
- Compare laboratory data from contrived samples with real world performance statistics to
 establish a relationship between the lab-measured performance and real-world performance.
 The goal is to develop rapid, laboratory-based methods that sufficiently assess the test
 performance, without the need of clinical or real-life testing. Completion of this aim will enable
 faster deployment of new laboratory-based tools for future outbreaks and in the analysis of new
 emerging variants of SARS-CoV-2.
- Evaluate usability of the antigen tests for self-testing and evaluate results of a weekly testing regime. We will conduct semi-structured in-depth interviews, surveys, in-person and remote usability and diary studies, and we will collect, analyze, and report user feedback.
- Develop a digital reporting system that can be used to collect and report test results in real-time
 to healthcare authorities. We will improve the user interface of the reporting application used to
 record and interpret test results based on participant and administrator feedback. We will
 develop a system of real-time reporting of test results which communicates directly with public
 health authorities in the City of Chelsea, in addition to developing more generalized
 epidemiological reporting capabilities for future implementation.







Chelsea Board of Health Meeting

Tuesday, March 8, 2022

Ann Marie Kissel, MPH (NSPHC-MAPC) Regional Epidemiologist






Age Group

Chelsea, Massachusetts


Source: Massachusetts COVID-19 vaccination data and updates | Mass.gov





Multiple Layers Improve Success

The Swiss Cheese Respiratory Pandemic Defense recognizes that no single intervention is perfect at preventing the spread of the coronavirus. Each intervention (layer) has holes.




Source: Adapted from Ian M. Mackay (virologydownunder.com) and James T. Reason. Illustration by Rose Wong

The Previous CDC's COVID-19 Community Transmission Levels

| Community Transmission Levels | CSO Transactioning | Moderate Transmission | Substantial Transmission | |
|--|-----------------------|--------------------------|-----------------------------|--------|
| Total new cases per 100,000 persons in the past 7 days | 0-9.99 | 10-49:99 | 50-99.99 | '≥100 |
| Percentage of NAATs that are positive during the past 7 days | 0-4.99% | 5-7.99% | 8-9.99% | ≥10.0% |

COVID-19 County Check Tool | CDC

he Previous Levels of Community Transmission of All Counties in US



Community Transmission in US by County

| | Total | Percent | %.Change |
|-------------|-------|---------|----------|
| High | 2984 | 92.61% | -5.52% |
| Substantial | 152 | 4.72% | 3.94% |
| Moderate | 36 | 1.12% | 0.87% |
| Low | 49 | 1.52% | 0.74% |

How is community transmission calculated?

As of 2/21/2022 CDC COVID Data Tracker

Layered Prevention Strategies

"We want to give people a break from things like masking when our levels are low, and then have the ability to reach for them again should things get worse in the future. We need to be prepared and we need to be ready for whatever comes next."

-Dr. Rochelle Walensky, the C.D.C.'s director

CDC's COVID-19 Community Levels

2020 Metrics

Transmission:

- 1. Total new cases per 100,000 persons in the past 7 days
- 2. Percentage of NAATs that are positive during the past 7 days

| Percentage of NAATs that are positive during the past 7 days | 0-4.99% | 5-7.99% | 8-9.99% | ≥10.0% |
|--|---------|--------------------------|------------------------|--------|
| Total new cases per 100,000 persons in the past 7 days | 0-9.99 | 10-49.99 | 50-99.99 | 2100 |
| Community Transmission Levels | | Moderate Transmission | Score on transferen | |

2022 Metrics

Transmission (leading indicator):

- Total new cases per 100,000 persons in the past 7 days
 Severity:
- New COVID-19 admissions per 100,000 population (7-day total)
 Anyone w/ COVID-19 diagnosis "for or with COVID"

Burden on Healthcare System:

3. Percent of staffed inpatient beds occupied by COVID-19 patients (7-day average)

| COAH | 0-19 Community Levels - Use the Highest L | ever svat vbbses to | tour cammunity | · |
|--|---|---------------------|----------------|----------|
| New CDVID-19 Cases Per 100,000 people in the past 7 days | Indicators | | Medium | нул |
| Fewer than 200 | New COVID-19 admissions per 100,000 population (7-day total) | 100 | 10,0-19.9 | 420.0 |
| | Percent of staffed inpatient beds occupied by COVID-19 patients (7-day average) | | 10:0-14.9% | #15.0% |
| | New COVID-19 admissions per 100,000 population (7-day total) | NA. | ÷10.0 | ¥100 |
| 200 or more | Percent of staffed inpatient beds occupied by COVID-19 patients (7-day average) | NA . | <10.0% | #175.09k |

COVID-19 Community Levels | CDC

CDC's COVID-19 Community Levels Goals

- Community measures should focus on minimizing the impact of severe COVID-19 illness on health and society
 - Preventing medically significant illness
 - Minimizing burden on the healthcare system
 - Protecting the most vulnerable through vaccines, therapeutics, and COVID-19 prevention

PowerPoint Presentation (cdc.gov

I hought Process: CDC's COVID-19 Community Transmission Levels

- 1. Current high levels of population immunity reduce risk of severe outcomes
 - · High rates of vaccination in population as a whole
 - · Availability of boosters, and booster coverage among populations at high risk
 - In unvaccinated, high rates of infection-induced protection
- 2. <u>Breadth of tools available</u> for public health and clinical care Broad access to vaccines, therapeutics, testing
- 3. Larger emphasis on medically significant disease and healthcare strain
- 4. Utilize data that represents national coverage at a county level
- . Embraces individual-level decision-making


Vulnerable populations who may consider staying masked (some or all of the time) based on:


- Age
- Health status
- Occupation
- Unvaccinated
- 6. "The proposed COVID-19 community levels provide a sizeable improvement over the community transmission levels in identifying regions that will experience severe outcomes 3 weeks later" CDC.gov
 - Deaths
 - ICU utilization

U.S. COVID-19 Community Levels by County Map

Updated Mar. 3, 2022 Languages ▼

Data provided by CDC Updated: March 3, 2022







COVID-19 Community Levels | CDC

CDC's COVID-19 Community Transmission Levels

| COVID | 0-19 Community Levels – Use the Highest L | evel that Applies to | Your Community | |
|--|---|----------------------|----------------|-------------------|
| New COVID-19 Cases Per 100,000 people in the past 7 days | Indicators | wedj | Medium | High |
| Fewer than 200 | New COVID-19 admissions per 100,000 population (7-day total) | #10.0 #10.0 | 10.0-19.9 | ≥20.0 |
| | Percent of staffed inpatient beds occupied by COVID-19 patients (7-day average) | 81D 996 | 10.0-14.9% | > 15.0% |
| | New COVID-19 admissions per 100,000 population (7-day total) | NÁ. | <10.0 | 210.0 |
| 200 or more | Percent of staffed inpatient beds occupied by COVID-19 patients (7-day average) | NA. | <10.0% | ≥ 10.0% |



Pneumonia, Influenza, and COVID-19 Mortality from the National Center for Health Statistics Mortality Surveillance System (data as of 2/3/2022)



Concerns with New Community Levels Framework

"my mask protects
you; your mask
protects me."

Prevention

"Test to Treat"

Reducing
transmission


Reducing
severity

Barriers

- Access to care is not ubiquitous or consistent among all
 - Un-insured (-31 million 2020 census)
 - Under-insured
 - PCP (1/4 US residents don't have a PCP)
 - Rural areas
- Not everyone is vaccinated, eligible for the COVID-19 vaccine (under 5), or unequal vaccine effectiveness (pediatrics)
- COVID-19 impacts have disproportionate effects in severity
 - Occupation
 - Age
 - Housing
 - Race/ethnicity
 - Low-income individuals/families
 - Individuals at risk of severe disease

Immunocompromised or high risk for severe disease individuals

"Based on the current evidence, a person with any of the conditions listed below is more likely to get very sick from COVID-19. This means that a person with one or more of these conditions who gets very sick from COVID-19 (has severe illness from COVID-19) is more likely to:



- Be hospitalized
- Need intensive care
- Require a ventilator to help them breathe
- Die"

Scientific Evidence for Conditions Associated with Higher Risk for Severe COVID-19 | CI

Conditions that Increase Risk of Severe Illness

- Bronchiectasis
- Cancer
- Cerebrovascular disease
- Chronic kidney disease
- Chronic liver disease (cirrhosis, non-alcoholic fatty liver disease, alcoholic liver disease, autoimmune hepatitis)
- COPD
- Cystic fibrosis
- Diabetes mellitus, type 1
- Diabetes mellitus, type 2
- Disabilities, including Down Syndrome
- HIV
- · Heart conditions (such as heart failure, coronary artery disease, or cardiomyopathies)
- Interstitial lung disease
- Mental health conditions (such as mood disorders, including depression, and schizophrenia spectrum
 disorders)

 Scientific Evidence for Conditions Associated with Higher Risk for Severe COVID-19 | Cl